Ruth Motter

11.5k citations

25 papers · 2.6k indexed · 2 hit papers · h-index 18

Co-authors: Peter Seubert Dale Schenk Kelly Johnson‐Wood Ivan Lieberburg Robin Barbour Dora Games Douglas Galasko Christopher M. Clark
Topics: Alzheimer's disease research and treatments (18 papers)Dementia and Cognitive Impairment Research (4 papers)Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers)
Cited by: Physiology Neurology Psychiatry and Mental health
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Neuroscience
Partner nations: United States Canada Ireland

In The Last Decade

Ruth Motter

25 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

1995 568 citations Ruth Motter, Dora Kholodenko et al. profile →
Amyloid precursor protein processing and Aβ ₄₂ deposition in a transgenic mouse model of Alzheimer disease

1997 553 citations Kelly Johnson‐Wood, Ruth Motter et al. profile →

Peers

Countries citing papers authored by Ruth Motter

Since Specialization

Citations

This map shows the geographic impact of Ruth Motter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Motter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Motter more than expected).

Fields of papers citing papers by Ruth Motter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Motter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Motter. The network helps show where Ruth Motter may publish in the future.

Co-authorship network of co-authors of Ruth Motter

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Motter. A scholar is included among the top collaborators of Ruth Motter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Motter. Ruth Motter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual-Toxin (“Bivalent”) Infant Botulism in California, 1976-2020: Epidemiologic, Clinical, and Laboratory Aspects 2022 ·The Journal of Pediatrics ·(unknown),(unknown),(unknown),Jason R. Barash,Ruth Motter,Nir Dover,Stephen S. Arnon	3
2	Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity 2018 ·Vaccine ·(unknown),Ruth Motter,Stephen S. Arnon	26
3	Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Albert W. Garofalo,Marc Adler,Danielle L. Aubele,Elizabeth Brigham,David Chian,Maurizio Franzini,Erich Goldbach,(unknown),Ruth Motter,Gary D. Probst,Kevin P. Quinn,Lany Ruslim,Hing L. Sham,Danny Tam,(unknown),Anh P. Truong,(unknown),Zhao Ren	23
4	In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain 2013 ·Neuroscience ·M. Bergeron,Ruth Motter,(unknown),(unknown),M. A. Babcock,(unknown),(unknown),(unknown),J. P. Anderson	42
5	Development of an enzyme-linked immunosorbent assay (ELISA) to measure the level of tyrosine hydroxylase protein in brain tissue from Parkinson's disease models 2013 ·Journal of Neuroscience Methods ·(unknown),Ruth Motter,(unknown),Armanda Rodrigues,(unknown),Linnea Diep,(unknown),Pui Seto,Kevin Tanaka,Jeanne Baker,Marcelle Bergeron	13
6	Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4 2011 ·Journal of Pharmaceutical and Biomedical Analysis ·Reneé Shapiro,Tatiana Plavina,Brian Schlain,R. Blake Pepinsky,Ellen A. Garber,Matthew Jarpe,Paula S. Hochman,Nancy Wehner,Frédérique Bard,Ruth Motter,Ted Yednock,Frederick R. Taylor	28
7	A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease 2010 ·Alzheimer Disease & Associated Disorders ·Ronald S. Black,Reisa A. Sperling,Beth Safirstein,Ruth Motter,Allan Pallay,Alice I. Nichols,Michael Grundman	136
8	Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse 2008 ·Neurodegenerative Diseases ·Peter Seubert,Robin Barbour,Karen Khan,Ruth Motter,(unknown),Dora Kholodenko,(unknown),Dale Schenk,Kelly Johnson‐Wood,Sally Schroeter,Davinder Gill,J. Steven Jacobsen,Menelas N. Pangalos,Guriqbal S. Basi,Dora Games	55
9	Active β-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of β-Amyloid 2007 ·Journal of Neuroscience ·Guiquan Chen,Karen Chen,Dione Kobayashi,Robin Barbour,Ruth Motter,Dora Games,Stephen J. Martin,Richard Morris	41
10	Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice 2007 ·Journal of Biological Chemistry ·Lisa McConlogue,Manuel Buttini,John P. Anderson,Elizabeth Brigham,Karen Chen,Stephen B. Freedman,Dora Games,Kelly Johnson‐Wood,Michael Lee,(unknown),Weiqun Liu,Ruth Motter,Sukanto Sinha	231
11	Distribution of Aβ peptide in whole blood 2006 ·Journal of Chromatography B ·J. Randall Slemmon,Cory L. Painter,Sashi Nadanaciva,(unknown),(unknown),Ruth Motter,Peter Seubert	11
12	β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease 2005 ·Journal of Neuroscience ·Manuel Buttini,Eliezer Masliah,Robin Barbour,(unknown),Ruth Motter,Kelly Johnson‐Wood,Karen Khan,Peter Seubert,Stephen B. Freedman,Dale Schenk,Dora Games	135
13	Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered β-amyloid in mice 2001 ·Vaccine ·David J. Brayden,(unknown),Siobhán McClean,Robin Barbour,Jiping Huang,(unknown),(unknown),Ruth Motter,Kelly Johnson‐Wood,Nicki Vasquez,Dale Schenk,Peter Seubert	18
14	Longitudinal stability of CSF tau levels in Alzheimer patients 1999 ·Biological Psychiatry ·Trey Sunderland,Benjamin Wolozin,Douglas Galasko,James Levy,Ruth Dukoff,Marcel Bahro,Robert Lasser,Ruth Motter,Terho Lehtimäki,Peter Seubert	82
15	Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans 1998 ·Neuroscience Letters ·Ronald J. Ellis,Peter Seubert,Ruth Motter,Douglas Galasko,Reena Deutsch,Robert K. Heaton,Melvyn P. Heyes,J. Allen McCutchan,J. Hampton Atkinson,Igor Grant	32
16	High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype 1998 ·Archives of Neurology ·Douglas Galasko,L. Chang,Ruth Motter,Christopher M. Clark,Jeffrey Kaye,David S. Knopman,Ronald G. Thomas,Dora Kholodenko,Dale Schenk,Ivan Lieberburg,Bruce L. Miller,(unknown),(unknown),(unknown),Michael A. Boss,Peter Seubert	369
17	The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments 1997 ·Journal of Neurochemistry ·G V Johnson,Peter Seubert,(unknown),Ruth Motter,Jason P. Brown,Douglas Galasko	133
18	Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease 1997 ·Neurology ·Doug Galasko,Christopher M. Clark,Lei Chang,Barney E. Miller,(unknown),Ruth Motter,Peter Seubert	110
19	The Effect of Apolipoprotein E Genotype on Biochemical Markers of Alzheimer's Disease 1996 ·Annals of the New York Academy of Sciences ·Dale Schenk,Ivan Lieberburg,Ruth Motter,Peter Seubert	1
20	Investigation of an Outbreak of Moraxella Conjunctivitis at a Navajo Boarding School 1989 ·American Journal of Ophthalmology ·Benjamin Schwartz,Lee H. Harrison,(unknown),Ruth Motter,Allen W. Hightower,Claire V. Broome	21

About Ruth Motter

Ruth Motter is a scholar working on Physiology, Neurology and Cellular and Molecular Neuroscience, having authored 25 papers that have together received 2.6k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (18 papers), Dementia and Cognitive Impairment Research (4 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers). The work is most often cited by research in Physiology (2.2k citations), Neurology (463 citations) and Psychiatry and Mental health (803 citations). Ruth Motter has collaborated with scholars based in United States, Canada and Ireland. Frequent co-authors include Peter Seubert, Dale Schenk, Kelly Johnson‐Wood, Ivan Lieberburg, Robin Barbour, Dora Games, Douglas Galasko, Christopher M. Clark, Dora Kholodenko and Lisa McConlogue. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact